What to watch with FTO and menopause?

The FTO gene (e.g., rs9939609) is the most robust genetic locus associated with higher BMI and obesity risk. During menopause, declining estrogen levels often lead to metabolic changes, increased abdominal fat, and weight gain. Some research suggests that FTO risk allele carriers may experience more pronounced weight gain during this transition, but the effect is small and heavily modulated by diet, physical activity, and sleep. No large randomized trials have tested FTO-based interventions for menopause management. Therefore, while the genetic link is plausible (GWAS evidence), its clinical utility for personalized menopause care is limited. Instead of relying solely on a DNA test, focus on evidence-based lifestyle strategies: strength training, adequate protein intake, and monitoring of metabolic markers (glucose, lipids, blood pressure). A DNA test can be a conversation starter but not a prescription. Evidence level: gwas/mixed. Safety note: Do not use genetic results to self-diagnose or alter hormone therapy without medical supervision.